Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.
“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza ...
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
Seasonal influenza epidemics impose substantial burdens on healthcare systems and cause >5 million hospitalizations of adults each year.
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback